FIELD: biotechnology.
SUBSTANCE: monoclonal antibody and its antigen-binding fragment which bind human factor XI are disclosed. Also disclosed are a nucleic acid coding said antibody, an expression vector, a host cell for producing the antibody. Invention also relates to pharmaceutical compositions and methods of treating a thromboembolic disease using an anti-factor XI antibody.
EFFECT: invention can be used for effective treatment of thromboembolic disease with reduced risk of haemorrhages.
20 cl, 16 dwg, 12 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ANTIBODIES AGAINST XI FACTOR AND THEIR APPLICATIONS | 2017 |
|
RU2758160C2 |
| ANTIBODIES AGAINST XI CLOTTING FACTOR | 2017 |
|
RU2757314C2 |
| NOVEL HUMANISED ANTIBODIES TO FACTOR XI WITH ANTITHROMBOTIC AND ANTI-INFLAMMATORY ACTION AND USE THEREOF | 2020 |
|
RU2817219C2 |
| ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF THE USE THEREOF | 2015 |
|
RU2766094C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| ANTI-DR5 ANTIBODY AND USE THEREOF | 2018 |
|
RU2735956C1 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
